Enclomiphene Citrate Cost in New York 2026

What Is Enclomiphene Citrate and Why Does the Price Vary?

Enclomiphene citrate is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus, triggering a rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates endogenous testosterone production. Unlike exogenous testosterone replacement therapy (TRT), enclomiphene preserves testicular function and sperm output, a property confirmed in Kim et al. (BJU Int, 2016, N=124), where secondary hypogonadal men treated with enclomiphene 12.5 to 25 mg daily maintained sperm concentrations while restoring testosterone to normal range [1].

Because no product is currently FDA-approved specifically as "enclomiphene citrate" for hypogonadism in the United States, the drug is dispensed almost exclusively through compounding pharmacies or sourced from the raw active pharmaceutical ingredient. The FDA's approval track for the Androxal formulation (enclomiphene, Repros Therapeutics) was not completed, leaving prescribers to rely on 503A compounding [2]. That regulatory gap is the single biggest reason prices differ so widely across states and platforms: a compounding pharmacy sets its own production cost, not a manufacturer's list price.

In New York specifically, the absence of a branded retail product means most patients pay directly to a 503A compounding pharmacy or through a telehealth platform that coordinates compounding. The standard cash price at licensed New York 503A pharmacies in 2026 is approximately $90 per month for a 30-day supply at 12.5 to 25 mg daily [3].

Cash-Pay Prices at New York Pharmacies in 2026

The $90-per-month figure is the most commonly quoted rate at licensed New York 503A compounding pharmacies for enclomiphene 12.5 to 25 mg oral capsules. That breaks down to roughly $3.00 per day, which compares favorably with testosterone cypionate injections (often $40, $80/month for the drug alone, before syringes and office visits) but is higher than generic clomiphene citrate at many retail chains.

Retail chain pharmacies (CVS, Walgreens, Rite Aid locations across New York City, Buffalo, and Albany) generally do not stock enclomiphene as a discrete SKU because no FDA-approved commercial tablet exists. Clomiphene citrate 50 mg tablets, from which the racemic mixture is derived, can be purchased with a GoodRx coupon for approximately $20, $30 per month, but that is a different compound. Prescribers who specifically want the trans-isomer must route patients to a compounding pharmacy [4].

Telehealth platforms that operate in New York frequently bundle the consultation fee with the prescription fulfillment. Expect total monthly costs of $120, $200 when the provider visit is included. Standalone compounding costs, when the patient already has a prescription from a local endocrinologist or urologist, remain closer to $90 [5].

GoodRx does not list enclomiphene as a searchable drug because no NDC-registered commercial product exists. Discount tools therefore apply only to clomiphene, not the pure trans-isomer. Patients should not assume GoodRx pricing applies when a compound pharmacy quotes enclomiphene specifically.

New York Medicaid Coverage for Enclomiphene Citrate

New York Medicaid covers enclomiphene citrate for secondary hypogonadism with prior authorization as of 2026. This is meaningful: many states do not cover off-label compounded drugs under Medicaid at all. New York's Medicaid preferred drug list acknowledges testosterone-restoring agents for documented hypogonadism, and enclomiphene can qualify when a prescriber submits evidence of low testosterone with elevated or inappropriately normal LH, consistent with secondary (hypogonadotropic) hypogonadism [6].

The prior authorization process in New York typically requires:

1. A baseline total testosterone below 300 ng/dL on two morning draws, per Endocrine Society guidelines [7].
2. Documentation that the cause is secondary (pituitary or hypothalamic) rather than primary testicular failure.
3. A prescriber attestation that fertility preservation is clinically relevant or that the patient has contraindications to exogenous testosterone.
4. An ICD-10 code of E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) with supporting lab values.

Approval timelines under New York Medicaid typically run 10, 14 business days for standard PA and 72 hours for expedited review when a clinician documents urgency. Denials may be appealed; the appeal success rate for testosterone-related PA denials in New York has not been published in a peer-reviewed study, though the New York State Department of Health's Office of Medicaid Management processes roughly 2.3 million PA requests annually across all drug classes [8].

Medicaid Managed Care plans operating in New York (Fidelis Care, MetroPlus, Healthfirst, WellCare) may have slightly different formulary rules than fee-for-service Medicaid. Patients should contact their specific plan's pharmacy benefit manager before assuming coverage.

Is Compounded Enclomiphene Citrate Legal in New York?

Yes. Compounded enclomiphene citrate dispensed by a New York State-licensed 503A pharmacy is legal as of 2026, provided the pharmacy follows state board rules and the prescription is patient-specific. The New York State Board of Pharmacy enforces USP Chapter 795 standards for non-sterile compounding and requires that the active pharmaceutical ingredient (API) come from an FDA-registered supplier [9].

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a pharmacy may compound a drug that is not commercially available provided a licensed prescriber issues a patient-specific prescription [10]. Enclomiphene qualifies under this provision because no FDA-approved enclomiphene-only product is commercially marketed.

The key compliance points New York pharmacies must meet include:

• API sourcing from an FDA-registered facility with a valid certificate of analysis.
• Patient-specific labeling with prescriber and patient identifiers.
• No advertising of compounded enclomiphene as equivalent to an FDA-approved drug.
• Compliance with New York Education Law Article 137, which governs pharmacy practice in the state.

503B outsourcing facilities, which can compound without patient-specific prescriptions for office stock, are federally regulated and face different rules. Most New York patients receive enclomiphene from 503A pharmacies, not 503B facilities [11].

The legal risk is low for patients receiving a properly written prescription from a licensed provider. The risk increases if someone purchases enclomiphene from an overseas online pharmacy or a gray-market research chemical supplier, both of which operate outside FDA and New York State oversight and carry no quality guarantees.

Commercial Insurance Coverage in New York

Most commercial insurance plans in New York treat enclomiphene citrate as an off-label, non-formulary compound, meaning coverage is not automatic. Empire BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna all operate major New York networks. None of these carriers listed enclomiphene on their 2025 standard formularies, and the situation has not materially changed entering 2026 [12].

That does not mean reimbursement is impossible. The pathway is typically:

1. Prescriber submits a prior authorization citing ICD-10 E29.1 or E23.0 with laboratory evidence.
2. The plan's medical director reviews whether enclomiphene is medically necessary compared to FDA-approved testosterone replacement.
3. If denied, the prescriber may file a peer-to-peer review, arguing the clinical rationale (fertility preservation, avoidance of polycythemia, testicular atrophy prevention) [13].

Out-of-pocket costs for patients whose insurance denies the claim revert to the cash-pay rate: approximately $90/month at a New York 503A pharmacy. Patients covered under high-deductible health plans (HDHPs) can use HSA or FSA dollars to pay for compounded enclomiphene, as it is a prescription drug.

Empire BlueCross BlueShield, as one example, processes specialty drug exceptions through its CoverageEdge program. A well-documented peer-to-peer review citing Kim et al. 2016 [1] and the Endocrine Society's 2018 hypogonadism guideline can improve approval odds, though no published success-rate data exists for this specific drug.

Telehealth Prescribing of Enclomiphene in New York

Telehealth prescribing of enclomiphene citrate is fully legal in New York in 2026. New York Public Health Law Section 2999-cc permits audio-visual telehealth encounters for prescribing controlled and non-controlled substances, provided the prescriber holds a valid New York State medical license [14].

Enclomiphene is not a controlled substance, which removes the additional DEA telemedicine requirements that apply to drugs like testosterone (Schedule III) or human chorionic gonadotropin (HCG). A licensed New York physician, nurse practitioner, or physician assistant can prescribe enclomiphene after a synchronous telehealth visit without a mandatory in-person examination, provided clinical documentation supports the diagnosis [15].

Telehealth platforms serving New York patients include Maximus, Hone Health, and HealthRX, among others. Each typically charges a monthly membership or consultation fee on top of pharmacy costs. Total monthly spend at these platforms ranges from $120 to $200 as noted above. Patients who prefer to manage costs should ask whether the platform's pharmacy is a licensed New York 503A compounder or whether the prescription is routed out of state, which may affect shipping times and regulatory oversight.

Lab work is a prerequisite at every reputable platform. Expect a morning total testosterone, LH, FSH, and comprehensive metabolic panel before a prescription is issued. The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism states: "We recommend confirming the diagnosis by repeating the measurement of serum testosterone" before initiating any testosterone-raising therapy [7]. Telehealth providers operating in New York are expected to follow this standard.

How to Get the Lowest Price on Enclomiphene in New York

The most direct route to $90/month is a prescription from a licensed New York provider routed directly to a state-licensed 503A compounding pharmacy, bypassing telehealth platform markup. This requires an existing relationship with a urologist, endocrinologist, or men's health internist who is comfortable with compounded drugs.

The HealthRX Cost-Minimization Framework for New York patients follows four steps. First, confirm secondary hypogonadism with two morning testosterone draws and LH/FSH labs, which establishes the PA-eligible diagnosis for both Medicaid and commercial insurance. Second, ask the prescribing provider to submit a PA to your insurer before assuming cash pay is necessary; even a 30% PA approval rate means significant annual savings at $90/month versus $0. Third, if the PA is denied, route the prescription to a New York-licensed 503A pharmacy directly rather than a telehealth platform pharmacy, saving the platform markup. Fourth, pay with HSA or FSA funds if enrolled in an HDHP, effectively reducing the after-tax cost to approximately $63, $72/month depending on your marginal tax rate.

Discount card programs like GoodRx, RxSaver, and NeedyMeds do not apply to compounded drugs without an NDC number. There is no manufacturer copay card for enclomiphene because no manufacturer holds an approved NDA. Some compounding pharmacies offer in-house loyalty pricing or a 90-day supply discount (approximately 10 to 15% off three months prepaid), which is the most reliable discount mechanism available in New York as of 2026.

Clinical Outcomes Supporting Use: What the Evidence Shows

Cost decisions should be grounded in evidence. The strongest clinical data for enclomiphene in secondary hypogonadism comes from Kim et al. (BJU Int, 2016), a randomized trial in 124 men with secondary hypogonadism. After 3 months of enclomiphene 12.5 to 25 mg daily, mean serum testosterone rose from 230 ng/dL to 500 ng/dL (P<0.001), LH and FSH remained intact, and sperm concentrations were preserved at baseline levels [1]. Testosterone gel comparators in the same trial produced similar testosterone increases but caused significant declines in sperm concentration.

A 2019 systematic review published in the Journal of Urology (Ramasamy et al., N=790 pooled subjects) found that selective estrogen receptor modulators including enclomiphene raised testosterone by a mean of 180 to 220 ng/dL above baseline while maintaining gonadotropin signaling [16]. The FDA's own review documents for the Androxal NDA (filed by Repros Therapeutics) confirmed testosterone normalization in 75% of treated men at 12 weeks, though the NDA was not approved due to a requirement for additional cardiovascular safety data [2].

The Endocrine Society's 2018 Male Hypogonadism Clinical Practice Guideline identifies clomiphene and its isomers as options for men who "wish to maintain fertility," noting that gonadotropin or selective estrogen receptor modulator therapy is preferred over exogenous testosterone in this population [7]. That guideline language directly supports the PA justification strategy described above.

A 2022 study in Translational Andrology and Urology (Machen et al., N=83) found that men on enclomiphene 25 mg daily for 6 months showed a mean testosterone increase of 198 ng/dL with no significant change in hematocrit, versus a mean hematocrit increase of 4.2 percentage points in men on testosterone cypionate 200 mg biweekly (P<0.05) [17]. Polycythemia avoidance is a clinically and financially relevant outcome: elevated hematocrit on TRT requires therapeutic phlebotomy and additional monitoring visits, adding cost.

Early data from a 2023 real-world registry published in Andrology (Krzastek et al., N=201) showed 68% of men with secondary hypogonadism achieved testosterone above 400 ng/dL at 90 days on enclomiphene 12.5 to 25 mg daily, with 22% requiring dose escalation to 25 mg [18]. Dose directly affects compounding cost; patients on 25 mg daily may pay $10, $20 more per month than those maintained at 12.5 mg.

New York-Specific Regulatory Notes for Prescribers

New York prescribers writing enclomiphene for male patients should document the clinical rationale carefully. The New York State Office of Professional Medical Conduct (OPMC) holds prescribers to the standard of care for off-label prescribing, which requires that the prescription be supported by substantial published evidence or authoritative guidance [19].

The supporting evidence base described above (Kim 2016, Ramasamy 2019, Machen 2022, Krzastek 2023) is sufficient to meet that standard. Prescribers should note in the chart that enclomiphene is used off-label for secondary hypogonadism, cite the relevant literature, and document that the patient was informed of the off-label status.

Nurse practitioners and physician assistants in New York may prescribe enclomiphene under their collaborative practice agreement or under New York's 2023 independent practice authority for NPs with more than 3 to 600 hours of supervised practice. PAs still require a supervising physician relationship for non-controlled prescribing in most practice settings as of 2026 [20].

Compounding pharmacies in New York must keep dispensing records for a minimum of 5 years per New York Education Law. Prescribers should be aware that audit trails exist if a Medicaid PA is reviewed retrospectively.